Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Clinical Questions Addressed by the CER (2)
The risk of nonmalignant adverse effects, such as development of CFRD, was evaluated by using studies of rhGH therapy, conducted in patients with CF, that reported blood glucose parameters, liver enzymes, or other adverse effects. Controlled trials and observational studies were included.
The risk of malignant adverse effects was evaluated by using studies of rhGH therapy, conducted in patients with CF, that reported on markers of cancer risk. Controlled trials and observational studies were included. Two epidemiological studies that reported incidence of cancer subsequent to rhGH treatment for idiopathic short stature or growth-hormone deficiency were also reviewed.
The impact of dose, duration, nutritional status, concurrent medical therapies, and patient subgroup characteristics on the effectiveness and safety of rhGH treatment in patients with CF was evaluated by using available data from included studies.
Keywords: CFRD | cystic fibrosis-related diabtes | CF-related diabetes | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.